{"log_id": 5650725433339603592, "direction": 0, "words_result_num": 82, "words_result": [{"probability": {"variance": 0.00553, "average": 0.963437, "min": 0.535277}, "location": {"width": 1151, "top": 77, "height": 40, "left": 136}, "words": "定的增加(3-4倍),小鼠微核试验结果提示,静脉注射利巴韦林剂量范围为20-200mg/kg时,具有诱裂作用。在显性致"}, {"probability": {"variance": 0.000938, "average": 0.988737, "min": 0.84388}, "location": {"width": 881, "top": 103, "height": 38, "left": 112}, "words": "死试验中,大鼠腹腔注射利巴韦林剂量范围为50-200mg/kg,连续5天,未见有致突变作用"}, {"probability": {"variance": 0.000367, "average": 0.991526, "min": 0.919467}, "location": {"width": 359, "top": 138, "height": 25, "left": 159}, "words": "生殖毒性:雄性小鼠给予剂量范围在"}, {"probability": {"variance": 0.003458, "average": 0.973088, "min": 0.695956}, "location": {"width": 708, "top": 126, "height": 40, "left": 579}, "words": "mg/kg时,可导致明显的生精管萎缩,精子浓度降低和形态异常的精子数"}, {"probability": {"variance": 0.007048, "average": 0.963363, "min": 0.604712}, "location": {"width": 1173, "top": 153, "height": 38, "left": 112}, "words": "量增加。停药后3-6个月,生精能力部分恢复,其它几项毒性试验也提示,成年大鼠经口给予利巴林剂量低至16mgkg"}, {"probability": {"variance": 0.002295, "average": 0.984276, "min": 0.716312}, "location": {"width": 1167, "top": 179, "height": 38, "left": 112}, "words": "时,可引起睾丸损伤(生精管萎缩),未进行更低剂量的研究。尚未对雌性动物的生殖能力进行研究。不同种属的动物"}, {"probability": {"variance": 0.00616, "average": 0.975148, "min": 0.473478}, "location": {"width": 1163, "top": 202, "height": 38, "left": 114}, "words": "研究已证实利巴韦林有明显的致畸和/或杀胚的潜在毒性。仓鼠单次经口给予本品剂量为2.5mg/kg或更大,家兔或大鼠"}, {"probability": {"variance": 0.00314, "average": 0.972579, "min": 0.670503}, "location": {"width": 1163, "top": 227, "height": 38, "left": 114}, "words": "的剂量分别为0.3和1.0mg/kg,结果均已证实有致畸作用。畸形主要发生在颅骨、、眼、四肢、颌骨、骨骼和胃肠道"}, {"probability": {"variance": 0.005559, "average": 0.968164, "min": 0.588856}, "location": {"width": 1169, "top": 252, "height": 38, "left": 114}, "words": "其发生率和严重程度随剂量的递增而增加。胎儿和子代的存活率降低。利巴韦林引起家兔和大鼠胚胎致死的剂量为1mg/kg"}, {"probability": {"variance": 0.001754, "average": 0.977796, "min": 0.8535}, "location": {"width": 301, "top": 286, "height": 27, "left": 114}, "words": "其无致畸作用剂量分别为0.1和"}, {"probability": {"variance": 0.002052, "average": 0.981231, "min": 0.807681}, "location": {"width": 575, "top": 284, "height": 25, "left": 517}, "words": "根据表面积推算,分别相当于人等效剂量0.015和0.04mg/kg"}, {"probability": {"variance": 0.006176, "average": 0.970847, "min": 0.498241}, "location": {"width": 1136, "top": 303, "height": 40, "left": 157}, "words": "致癌性:大鼠经擦食给予利巴韦林剂量为16-200mgkg长期研究结果提示,利巴韦林可能诱发良性乳房、胰管、垂体"}, {"probability": {"variance": 0.0058, "average": 0.977912, "min": 0.50729}, "location": {"width": 1171, "top": 328, "height": 38, "left": 112}, "words": "和臂上腺瘤。小鼠和大鼠的18-24个月的初步致癌试验并非最终结果,但这些试验证实,给予利巴韦林剂量分别为20-75"}, {"probability": {"variance": 0.005879, "average": 0.950305, "min": 0.786815}, "location": {"width": 77, "top": 365, "height": 21, "left": 114}, "words": "和10-40"}, {"probability": {"variance": 0.000546, "average": 0.994072, "min": 0.860514}, "location": {"width": 764, "top": 359, "height": 29, "left": 272}, "words": "小鼠和大鼠分别出现的血管损伤和视黄醛还原酶变性与利巴韦林长期给药有关"}, {"probability": {"variance": 8e-06, "average": 0.996438, "min": 0.990928}, "location": {"width": 128, "top": 385, "height": 29, "left": 120}, "words": "【药代动力学"}, {"probability": {"variance": 0.008204, "average": 0.963591, "min": 0.443439}, "location": {"width": 1188, "top": 400, "height": 75, "left": 101}, "words": "、国内人体生物利用度研究资料表明,利巴韦林颗粒口服后吸收迅速,在60-90分钟内血药浓度可达到峰值。利巴韦林"}, {"probability": {"variance": 0.002456, "average": 0.984631, "min": 0.654588}, "location": {"width": 1181, "top": 431, "height": 36, "left": 112}, "words": "进入体内后,经磷酸化生成具有活性的代谢产物利巴韦林单磷酸。消除半衰期约为24小时,利巴韦林能滞留于红细胞"}, {"probability": {"variance": 0.007466, "average": 0.964137, "min": 0.630006}, "location": {"width": 426, "top": 463, "height": 25, "left": 112}, "words": "内。主要由肾脏排泄,仅有少量随粪便排出"}, {"probability": {"variance": 0.000172, "average": 0.98589, "min": 0.968294}, "location": {"width": 44, "top": 488, "height": 23, "left": 159}, "words": "据Ph"}, {"probability": {"variance": 1.5e-05, "average": 0.981891, "min": 0.97808}, "location": {"width": 73, "top": 488, "height": 19, "left": 287}, "words": " Desk Re"}, {"probability": {"variance": 0.004298, "average": 0.980586, "min": 0.614459}, "location": {"width": 844, "top": 480, "height": 31, "left": 441}, "words": "54版)介绍,慢性肝炎患者服用利巴韦林单剂量和多剂量的药动性质概括在表1中。口"}, {"probability": {"variance": 0.002928, "average": 0.981608, "min": 0.607774}, "location": {"width": 1179, "top": 507, "height": 29, "left": 112}, "words": "服后利巴韦林吸收迅速而完全。然而由于首过效应,绝对生物利用度平均值为64%(44)。在单次服用200~1200mg剂量"}, {"probability": {"variance": 0.003889, "average": 0.977632, "min": 0.60278}, "location": {"width": 976, "top": 531, "height": 35, "left": 114}, "words": "范围内,利巴韦林的剂量与AUCa(从0时间到最后测试点之间的AUC)之间存在线性关系。但剂量与"}, {"probability": {"variance": 0.001485, "average": 0.982432, "min": 0.896274}, "location": {"width": 138, "top": 531, "height": 25, "left": 1147}, "words": "之间的关系呈"}, {"probability": {"variance": 0.001067, "average": 0.990443, "min": 0.825048}, "location": {"width": 521, "top": 562, "height": 25, "left": 114}, "words": "曲线性的,单剂量在400~600mg以上时趋近于渐近线"}, {"probability": {"variance": 0.010706, "average": 0.966394, "min": 0.410008}, "location": {"width": 1118, "top": 583, "height": 29, "left": 161}, "words": "多次口服后,可以观察到在血浆中有6倍的利巴韦林蓄积(以AUC12hr为基础)连续口服600mg,每日两次,大约四"}, {"probability": {"variance": 0.008405, "average": 0.964159, "min": 0.553582}, "location": {"width": 1183, "top": 609, "height": 31, "left": 112}, "words": "周可以达到稳态,稳态血浆平均浓度为2200(37%)ng/ml,停药后测量的平均半衰期为298(30%)小时,这表明本品可能存"}, {"probability": {"variance": 2.7e-05, "average": 0.996029, "min": 0.983097}, "location": {"width": 249, "top": 638, "height": 25, "left": 112}, "words": "在从非血浆部分缓慢消除"}, {"probability": {"variance": 0.001615, "average": 0.982262, "min": 0.769071}, "location": {"width": 1132, "top": 655, "height": 31, "left": 161}, "words": "食物对利巴韦林吸收的影响:在单剂量药物研究中,当利巴韦林与高脂肪餐(841千卡热量。53.8g脂肪,31.6g蛋白质"}, {"probability": {"variance": 0.002235, "average": 0.979916, "min": 0.709882}, "location": {"width": 1155, "top": 682, "height": 33, "left": 116}, "words": "和57.4g糖类)一同食用时, Auctt?和Cmax增加70%。尚没有足够的数据来证实这些结果的临床相关性。临床药效研究时"}, {"probability": {"variance": 0.000575, "average": 0.993081, "min": 0.883736}, "location": {"width": 494, "top": 710, "height": 29, "left": 114}, "words": "未进行关于食物消耗方面的说明。(见用法与用量"}, {"probability": {"variance": 0.000418, "average": 0.991031, "min": 0.870877}, "location": {"width": 1120, "top": 729, "height": 31, "left": 159}, "words": "抗酸剂对利巴韦林吸收的影响:服用利巴韦林的同时服用一种抗酸剂包含镁、铝和二甲硅油,会导致利巴韦林AUC"}, {"probability": {"variance": 0.003031, "average": 0.975077, "min": 0.745376}, "location": {"width": 605, "top": 756, "height": 31, "left": 112}, "words": "平均值下降14%.单剂量研究结果临床相关性未知。[见表1]"}, {"probability": {"variance": 0.002342, "average": 0.989201, "min": 0.720405}, "location": {"width": 698, "top": 788, "height": 29, "left": 161}, "words": "表1慢性肝炎成年患者服用利巴韦林后的平均药代动力学参数(N=12"}, {"probability": {"variance": 0, "average": 0.998684, "min": 0.998684}, "location": {"width": 21, "top": 830, "height": 21, "left": 260}, "words": "参"}, {"probability": {"variance": 0, "average": 0.999323, "min": 0.999323}, "location": {"width": 23, "top": 830, "height": 21, "left": 338}, "words": "数"}, {"probability": {"variance": 4.5e-05, "average": 0.994522, "min": 0.97994}, "location": {"width": 287, "top": 825, "height": 31, "left": 751}, "words": "利巴韦林剂量(变异系数)"}, {"probability": {"variance": 3e-06, "average": 0.998119, "min": 0.995491}, "location": {"width": 95, "top": 860, "height": 27, "left": 527}, "words": "单剂量6"}, {"probability": {"variance": 2.7e-05, "average": 0.99683, "min": 0.980686}, "location": {"width": 241, "top": 858, "height": 29, "left": 920}, "words": "多剂量600mg每日两次"}, {"probability": {"variance": 0.01462, "average": 0.793069, "min": 0.708882}, "location": {"width": 93, "top": 900, "height": 21, "left": 142}, "words": " Imax(hn"}, {"probability": {"variance": 0.004645, "average": 0.957294, "min": 0.839376}, "location": {"width": 50, "top": 900, "height": 21, "left": 550}, "words": "7(46"}, {"probability": {"variance": 1e-06, "average": 0.998501, "min": 0.997457}, "location": {"width": 31, "top": 898, "height": 21, "left": 943}, "words": "60"}, {"probability": {"variance": 0.00014, "average": 0.990729, "min": 0.962685}, "location": {"width": 85, "top": 935, "height": 21, "left": 531}, "words": "782(37)"}, {"probability": {"variance": 0.000964, "average": 0.976268, "min": 0.913304}, "location": {"width": 89, "top": 970, "height": 23, "left": 529}, "words": "43.6(47"}, {"probability": {"variance": 0.003422, "average": 0.97069, "min": 0.839916}, "location": {"width": 83, "top": 970, "height": 23, "left": 920}, "words": "298(30"}, {"probability": {"variance": 0.00932, "average": 0.932185, "min": 0.746264}, "location": {"width": 163, "top": 1013, "height": 21, "left": 159}, "words": " Uctf(ng . h/ml)"}, {"probability": {"variance": 0.00104, "average": 0.96567, "min": 0.89642}, "location": {"width": 70, "top": 1005, "height": 21, "left": 972}, "words": "00(25)"}, {"probability": {"variance": 3e-06, "average": 0.997936, "min": 0.995298}, "location": {"width": 147, "top": 1040, "height": 29, "left": 143}, "words": "表观分布容积"}, {"probability": {"variance": 0, "average": 0.997147, "min": 0.997107}, "location": {"width": 21, "top": 1046, "height": 19, "left": 529}, "words": "28"}, {"probability": {"variance": 5e-06, "average": 0.998264, "min": 0.994107}, "location": {"width": 126, "top": 1077, "height": 25, "left": 142}, "words": "表观清除率"}, {"probability": {"variance": 2e-06, "average": 0.99822, "min": 0.994972}, "location": {"width": 173, "top": 1112, "height": 29, "left": 142}, "words": "绝对生物利用度"}, {"probability": {"variance": 0.001547, "average": 0.98718, "min": 0.752209}, "location": {"width": 1103, "top": 1149, "height": 29, "left": 161}, "words": "利巴韦林能进入红细胞内,并已被确认通过es-型核苷载体进入的。实质上这种类型载体存在于所有类型的细胞中"}, {"probability": {"variance": 0.00154, "average": 0.986243, "min": 0.806419}, "location": {"width": 519, "top": 1177, "height": 27, "left": 112}, "words": "可以导致分布容积扩大。利巴韦林与血浆蛋白结合少"}, {"probability": {"variance": 0.004083, "average": 0.979395, "min": 0.62094}, "location": {"width": 1126, "top": 1198, "height": 29, "left": 163}, "words": "利巴韦林有两种代谢途径:)一种是在有核细胞中可逆的磷酸化;()另一种是包括脱核糖基化和胺水解产生一种"}, {"probability": {"variance": 0.006897, "average": 0.964833, "min": 0.577849}, "location": {"width": 1146, "top": 1223, "height": 27, "left": 116}, "words": "三吡咯羧酸代谢物的代谢途径。利巴韦林及其三吡咯酰胺和三吡咯羧酸代谢物经肾排泄。口服600mg14C-利巴韦林后"}, {"probability": {"variance": 0.006364, "average": 0.978884, "min": 0.467503}, "location": {"width": 873, "top": 1249, "height": 29, "left": 114}, "words": "在336小时内在尿及粪便中分别有61%和12%左右消除,其中未经转化的利巴韦林只占17%"}, {"probability": {"variance": 4.6e-05, "average": 0.996589, "min": 0.964667}, "location": {"width": 1124, "top": 1274, "height": 31, "left": 163}, "words": "人及大鼠肝脏微粒体体外代谢研究结果表明:利巴韦林很少或几乎不通过细胞色素P450代谢,只有极少量潜在的酶"}, {"probability": {"variance": 8e-06, "average": 0.997413, "min": 0.992527}, "location": {"width": 184, "top": 1301, "height": 29, "left": 120}, "words": "药物之间相互作用"}, {"probability": {"variance": 2e-06, "average": 0.998967, "min": 0.996298}, "location": {"width": 89, "top": 1328, "height": 25, "left": 114}, "words": "特殊人群"}, {"probability": {"variance": 0.006573, "average": 0.961475, "min": 0.663616}, "location": {"width": 1111, "top": 1348, "height": 33, "left": 157}, "words": "肾功能障碍:患有不同程度的肾功能障碍的HCV感染患者口服单剂量(400mg)的利巴韦林后,肌酐清除率值在10"}, {"probability": {"variance": 0.016214, "average": 0.93843, "min": 0.352318}, "location": {"width": 1173, "top": 1373, "height": 31, "left": 116}, "words": "3m/min的患者较对照组(肌酐清除率>90m/min) Auctf值大了3倍:较肌酐清除率值在30~60mmin的患者AUC值大了"}, {"probability": {"variance": 6.5e-05, "average": 0.995575, "min": 0.952567}, "location": {"width": 1161, "top": 1402, "height": 27, "left": 124}, "words": "倍,这均是因为清除率下降减少了药物消除。多次给药后利巴韦林的药代参数很难预测。血液透析不能有效清除利巴"}, {"probability": {"variance": 0.000414, "average": 0.992086, "min": 0.897752}, "location": {"width": 706, "top": 1428, "height": 25, "left": 116}, "words": "韦林。肌酐清除率<50ml/min的患者,不推荐使用利巴韦林(见注意事项"}, {"probability": {"variance": 0.004637, "average": 0.96886, "min": 0.672926}, "location": {"width": 1128, "top": 1451, "height": 29, "left": 159}, "words": "肝功能障碍:具有轻、中、重度肝功能障碍患者(按 Child-pugh分类为A、B、C)分别口服单剂量(600mg)的利巴韦"}, {"probability": {"variance": 0.002959, "average": 0.986822, "min": 0.605064}, "location": {"width": 1175, "top": 1478, "height": 27, "left": 114}, "words": "林后,与对照组相比平均 Auctf值没有明显的不同。然而平均Cmax值随肝功能障碍的严重而增大,患有严重肝功能障碍"}, {"probability": {"variance": 0.00149, "average": 0.981916, "min": 0.843625}, "location": {"width": 313, "top": 1506, "height": 25, "left": 114}, "words": "的患者比对照组的Cmax值大2倍"}, {"probability": {"variance": 0.000156, "average": 0.994178, "min": 0.941033}, "location": {"width": 474, "top": 1527, "height": 33, "left": 161}, "words": "儿科患者:尚未对儿科患者进行详细药动学研究"}, {"probability": {"variance": 0.000305, "average": 0.994315, "min": 0.920625}, "location": {"width": 416, "top": 1552, "height": 25, "left": 165}, "words": "老年患者:尚未对老年患者进行药动学研究"}, {"probability": {"variance": 0.000104, "average": 0.995442, "min": 0.941699}, "location": {"width": 949, "top": 1574, "height": 29, "left": 159}, "words": "性别:在对18个男性患者及18个女性患者进行的单剂量研究中,没有发现明显的性别药动学不同"}, {"probability": {"variance": 3.4e-05, "average": 0.995377, "min": 0.980651}, "location": {"width": 334, "top": 1597, "height": 36, "left": 120}, "words": "【贮藏】密封,在干燥处保存"}, {"probability": {"variance": 0.000339, "average": 0.990209, "min": 0.928083}, "location": {"width": 443, "top": 1624, "height": 29, "left": 122}, "words": "【包装】复合膜袋装。12袋/盒:24袋/盒"}, {"probability": {"variance": 2e-06, "average": 0.997986, "min": 0.99588}, "location": {"width": 184, "top": 1653, "height": 29, "left": 134}, "words": "有效期】24个月"}, {"probability": {"variance": 2.4e-05, "average": 0.997092, "min": 0.981582}, "location": {"width": 400, "top": 1673, "height": 38, "left": 124}, "words": "【执行标准】《中国药典》2010年版二部"}, {"probability": {"variance": 0.000197, "average": 0.991708, "min": 0.945209}, "location": {"width": 305, "top": 1706, "height": 25, "left": 136}, "words": "批准文号】国药准字H2005944"}, {"probability": {"variance": 0, "average": 0.99965, "min": 0.999175}, "location": {"width": 93, "top": 1729, "height": 27, "left": 136}, "words": "生产企业"}, {"probability": {"variance": 3.8e-05, "average": 0.996123, "min": 0.979966}, "location": {"width": 387, "top": 1753, "height": 29, "left": 142}, "words": "企业名称:海南康芝药业股份有限公司"}, {"probability": {"variance": 3.3e-05, "average": 0.997227, "min": 0.971862}, "location": {"width": 768, "top": 1774, "height": 29, "left": 143}, "words": "生产地址:海南省海口国家高新技术产业开发区药谷工业园药谷三路6号"}, {"probability": {"variance": 1.1e-05, "average": 0.997872, "min": 0.98875}, "location": {"width": 163, "top": 1807, "height": 25, "left": 140}, "words": "邮政编码:5703"}, {"probability": {"variance": 0.012659, "average": 0.95893, "min": 0.507689}, "location": {"width": 252, "top": 1832, "height": 25, "left": 140}, "words": "电话号码:0898-66802060"}, {"probability": {"variance": 0.001489, "average": 0.983464, "min": 0.827053}, "location": {"width": 256, "top": 1856, "height": 27, "left": 142}, "words": "传真号码:0898-66802002"}, {"probability": {"variance": 0.007427, "average": 0.962454, "min": 0.510408}, "location": {"width": 649, "top": 1879, "height": 31, "left": 138}, "words": "学术咨询:0898-66802060(工作时间)、13926070793(休息时间)"}], "language": 3}